Posted on 04/05/2015 11:20:58 AM PDT by E. Pluribus Unum
Pharma heavyweight Novartis has stepped in to help bankroll Berkeley, CA-based Caribou Biosciences, one of the upstart leaders in the race to develop the cutting-edge CRISPR-Cas9 gene editing technology. The pharma giant joined a group of backers that includes Fidelity Biosciences, Mission Bay Capital, and 5 Prime as well as company founder Jennifer Doudna, a key player among a small group of investigators which has spawned a lineup of closely watched biotechs.
All together the group, which was also joined by an unnamed investor, provided $11 million in an A round to Caribou, which plans to use the cash to further advance technology spotlighted in projects at the University of California and the University of Vienna.
Doudna and her colleague Emmanuelle Charpentier, who also ventured out to start her own company, recently won the coveted Breakthrough Prize for their work with CRISPR-Cas9. Caribou co-founded Intellia, which went on to strike a landmark collaboration with the Novartis Institutes for Biomedical Research in Cambridge, MA. And the pharma giant--well known for its willingness to move fast and open its check book to new technologies--also helped seed the Atlas-based Intellia.
Novartis didn't offer any numbers about the Intellia partnership. But it did spell out its interest in using the work at Intellia Therapeutics on chimeric antigen receptor T cells (CAR-Ts) and hematopoietic stem cells with a broad interest in developing gene therapies.
CRISPR-Cas9 is a small but highly contentious field. Doudna, a structural biologist from Berkeley, was originally credited as a cofounder of Editas, another CRISPR-Cas9 player, before splitting away. She worked on gene editing with Charpentier, who threw her support behind CRISPR Therapeutics in Switzerland while MIT's Feng Zhang joined the Editas group. Their work is at a very early stage, but their story of reengineering genes has swiftly captured the attention of the industry. If the DNA-splicing technology works as the pioneers claim it does, the startups in the field are in the opening stages of making some major breakthroughs. But there has also been visible tension among the founding scientists over who owns the IP involved.
"CRISPR-Cas9 technology for gene editing is one of the most promising areas of scientific research today and Caribou, through its early work and its initial partnerships, has been a leader in this rapidly emerging field," remarked Robert Weisskoff, a partner at Fidelity Biosciences and newly appointed member of Caribou's Board of Directors. "We look forward to helping support the company as it continues to translate the promise of its platform across the enormously broad spectrum of commercial applications."
- here's the release
Note: this topic is from 4/05/2015. Thanks E. Pluribus Unum.Looked for it because of this article I read at the doc's office the other day:
Technical details aside, Crispr-Cas9 makes it easy, cheap, and fast to move genes around -- any genes, in any living thing, from bacteria to people. "These are monumental moments in the history of biomedical research," Baltimore says. "They don't happen every day."
Using the three-year-old technique, researchers have already reversed mutations that cause blindness, stopped cancer cells from multiplying, and made cells impervious to the virus that causes AIDS. Agronomists have rendered wheat invulnerable to killer fungi like powdery mildew, hinting at engineered staple crops that can feed a population of 9 billion on an ever-warmer planet. Bioengineers have used Crispr to alter the DNA of yeast so that it consumes plant matter and excretes ethanol, promising an end to reliance on petrochemicals...
Depending on what kind of person you are, Crispr makes you see a gleaming world of the future, a Nobel medallion, or dollar signs.
Cheap easy gene modification - what could go wrong?
Twelve Monkeys, ala Allah Akbar...
Or one hell of a Superbug. < |:(~
:’)
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.